256 related articles for article (PubMed ID: 32512316)
1. Nanomedicine to target multidrug resistant tumors.
Lepeltier E; Rijo P; Rizzolio F; Popovtzer R; Petrikaite V; Assaraf YG; Passirani C
Drug Resist Updat; 2020 Sep; 52():100704. PubMed ID: 32512316
[TBL] [Abstract][Full Text] [Related]
2. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
Bar-Zeev M; Livney YD; Assaraf YG
Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
[TBL] [Abstract][Full Text] [Related]
3. Insight on Multidrug Resistance and Nanomedicine Approaches to Overcome MDR.
Mohammad IS; He W; Yin L
Crit Rev Ther Drug Carrier Syst; 2020; 37(5):473-509. PubMed ID: 33389848
[TBL] [Abstract][Full Text] [Related]
4. Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy.
Beretta GL; Cavalieri F
Curr Med Chem; 2016; 23(1):3-22. PubMed ID: 26438248
[TBL] [Abstract][Full Text] [Related]
5. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
6. Overcoming multidrug resistance with nanomedicines.
Ganoth A; Merimi KC; Peer D
Expert Opin Drug Deliv; 2015 Feb; 12(2):223-38. PubMed ID: 25224685
[TBL] [Abstract][Full Text] [Related]
7. Nanomedicine therapeutic approaches to overcome cancer drug resistance.
Markman JL; Rekechenetskiy A; Holler E; Ljubimova JY
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1866-79. PubMed ID: 24120656
[TBL] [Abstract][Full Text] [Related]
8. Biofunctionalized polymer-lipid supported mesoporous silica nanoparticles for release of chemotherapeutics in multidrug resistant cancer cells.
Zhang X; Li F; Guo S; Chen X; Wang X; Li J; Gan Y
Biomaterials; 2014 Apr; 35(11):3650-65. PubMed ID: 24462359
[TBL] [Abstract][Full Text] [Related]
9. Nano-Engineered Mesenchymal Stem Cells Increase Therapeutic Efficacy of Anticancer Drug Through True Active Tumor Targeting.
Layek B; Sadhukha T; Panyam J; Prabha S
Mol Cancer Ther; 2018 Jun; 17(6):1196-1206. PubMed ID: 29592881
[TBL] [Abstract][Full Text] [Related]
10. Rationally designed nanovehicles to overcome cancer chemoresistance.
Livney YD; Assaraf YG
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1716-30. PubMed ID: 23954781
[TBL] [Abstract][Full Text] [Related]
11. Dual drug-paired polyprodrug nanotheranostics reverse multidrug resistant cancers via mild photothermal-cocktail chemotherapy.
Du C; Ding Y; Qian J; Zhang R; Dong CM
J Mater Chem B; 2019 Sep; 7(35):5306-5319. PubMed ID: 31411235
[TBL] [Abstract][Full Text] [Related]
12. Cargo-Free Nanomedicine with pH Sensitivity for Codelivery of DOX Conjugated Prodrug with SN38 To Synergistically Eradicate Breast Cancer Stem Cells.
Sun N; Zhao C; Cheng R; Liu Z; Li X; Lu A; Tian Z; Yang Z
Mol Pharm; 2018 Aug; 15(8):3343-3355. PubMed ID: 29923726
[TBL] [Abstract][Full Text] [Related]
13. Nanotechnology-based strategies as novel therapies in gliomas.
Gaikwad PS; Banerjee R
Ther Deliv; 2018 Aug; 9(8):571-592. PubMed ID: 30071804
[TBL] [Abstract][Full Text] [Related]
14. Computer-assisted engineering of programmed drug releasing multilayer nanomedicine via indomethacin-mediated ternary complex for therapy against a multidrug resistant tumor.
Che L; Liu Z; Wang D; Xu C; Zhang C; Meng J; Zheng J; Yuan H; Zhao G; Zhou X
Acta Biomater; 2019 Oct; 97():461-473. PubMed ID: 31344512
[TBL] [Abstract][Full Text] [Related]
15. Overcoming cellular multidrug resistance using classical nanomedicine formulations.
Kunjachan S; Błauż A; Möckel D; Theek B; Kiessling F; Etrych T; Ulbrich K; van Bloois L; Storm G; Bartosz G; Rychlik B; Lammers T
Eur J Pharm Sci; 2012 Mar; 45(4):421-8. PubMed ID: 21907796
[TBL] [Abstract][Full Text] [Related]
16. Novel nanomedicines to overcome cancer multidrug resistance.
Su Z; Dong S; Zhao SC; Liu K; Tan Y; Jiang X; Assaraf YG; Qin B; Chen ZS; Zou C
Drug Resist Updat; 2021 Sep; 58():100777. PubMed ID: 34481195
[TBL] [Abstract][Full Text] [Related]
17. RGD peptide-modified, paclitaxel prodrug-based, dual-drugs loaded, and redox-sensitive lipid-polymer nanoparticles for the enhanced lung cancer therapy.
Wang G; Wang Z; Li C; Duan G; Wang K; Li Q; Tao T
Biomed Pharmacother; 2018 Oct; 106():275-284. PubMed ID: 29966971
[TBL] [Abstract][Full Text] [Related]
18. Advances in Gold Nanoparticles: Synthesis, Functionalization Strategies, and Theranostic Applications in Cancer.
Damani M; Jadhav M; Joshi R; Singh BP; Momin MM; Ningthoujam RS; Khan T
Crit Rev Ther Drug Carrier Syst; 2024; 41(6):1-56. PubMed ID: 38804553
[TBL] [Abstract][Full Text] [Related]
19. Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles.
Chen Z; Zheng Y; Shi Y; Cui Z
Int J Nanomedicine; 2018; 13():319-336. PubMed ID: 29391792
[TBL] [Abstract][Full Text] [Related]
20. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
